AR072088A1 - Derivados de indol triciclicos y sus metodos de uso - Google Patents
Derivados de indol triciclicos y sus metodos de usoInfo
- Publication number
- AR072088A1 AR072088A1 ARP090102091A ARP090102091A AR072088A1 AR 072088 A1 AR072088 A1 AR 072088A1 AR P090102091 A ARP090102091 A AR P090102091A AR P090102091 A ARP090102091 A AR P090102091A AR 072088 A1 AR072088 A1 AR 072088A1
- Authority
- AR
- Argentina
- Prior art keywords
- butyl
- nhc
- nhch3
- alkylene
- alkyl
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 150000002475 indoles Chemical class 0.000 abstract 3
- 229940054051 antipsychotic indole derivative Drugs 0.000 abstract 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- -1 -NHCH3 Chemical group 0.000 abstract 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a derivados de indol tric¡clicos, composiciones que comprenden al menos un derivado tric¡clico de indol, y metodos de uso de los derivados de indol tric¡clicos para el tratamiento o la prevencion de una infeccion viral o un trastorno relacionado con virus en un paciente. Reivindicacion 1: Un compuesto que posee la formula (1) y sales, solvatos, esteres y prodrogas farmaceuticamente aceptables de los mismos, en donde la l¡nea punteada representa un enlace opcional y adicional, y en donde R1 es H, alquilo, alquenilo, -alquileno-OC(O)-alquilo, -alquilen-arilo, aminoalquilo o -alquilen-heterocicloalquilo; R2 es H, F, CI o -CH3; R3 es fenilo, naftilo, heterocicloalquilo que contiene nitrogeno, heterocicloalquenilo que contiene nitrogeno o heteroarilo que contiene nitrogeno, cualquiera de los cuales puede estar opcionalmente sustituido con hasta 3 grupos, que pueden ser iguales o diferentes, y se seleccionan de metilo, t-butilo, alilo, F, CI, Br, -CN, -O-CH2CH3, -S(O)CH3, -S(O)2CH3, -NH2, -OH, -CH2NH2, -C(O)NH2, -C(O)NHCH3, -C(O)NH-ciclopropilo, hidroxialquilo, -C(O)H, -C(O)CH3, -C(O)O-isopropilo, -C(O)O-t-butilo, -CH2C(O)-t-butilo, -OCH3, -NHCH3, -SCH3, -C(O)NHCH3, -NHC(O)OCH3, -NHC(O)O-isopropilo, -CH2N(CH3)2, -OC(O)CH(CH3)NHC(O)O-t-butilo, -OC(O)CH(CH3)NH2, -C(O)O-t-butilo, -CH2C(O)O-t-butilo, -OCH2CH2N(CH3)2, morfolinilo, -CH2OC(O)-t-butilo, -CH(=NOH), -CH(=NOCH3), -NHC(O)CH2N(CH3)2 y -NHC(O)O-t-butilo; y R4 es H o -C(O)O-alquilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6134408P | 2008-06-13 | 2008-06-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072088A1 true AR072088A1 (es) | 2010-08-04 |
Family
ID=40943627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102091A AR072088A1 (es) | 2008-06-13 | 2009-06-10 | Derivados de indol triciclicos y sus metodos de uso |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8901139B2 (es) |
| EP (1) | EP2303893B1 (es) |
| JP (1) | JP5580814B2 (es) |
| CN (1) | CN102159579B (es) |
| AR (1) | AR072088A1 (es) |
| CA (1) | CA2727620A1 (es) |
| MX (1) | MX2010013630A (es) |
| TW (1) | TW201011030A (es) |
| WO (1) | WO2009152200A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008082484A1 (en) | 2006-12-22 | 2008-07-10 | Schering Corporation | 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections |
| CN107573363A (zh) * | 2012-09-20 | 2018-01-12 | Udc 爱尔兰有限责任公司 | 供电子应用的氮杂二苯并呋喃和包含氮杂二苯并呋喃的电子器件 |
| ES2688147T3 (es) * | 2014-03-21 | 2018-10-31 | Bristol-Myers Squibb Company | Compuestos de 6H-furo[2,3-e]indol para el tratamiento de la hepatitis C |
| EP3131897B8 (en) | 2014-04-16 | 2022-08-03 | Merck Sharp & Dohme LLC | Factor ixa inhibitors |
| WO2018151239A1 (ja) * | 2017-02-17 | 2018-08-23 | 第一三共株式会社 | ３，６－ジヒドロ－２Ｈ－フロ［２，３－ｅ］インドール化合物 |
| CN116063310A (zh) * | 2022-12-23 | 2023-05-05 | 齐鲁工业大学 | 一种呋喃并[3,4-b]吲哚衍生物及其合成方法 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE648639C (de) | 1935-05-19 | 1937-08-05 | I G Farbenindustrie Akt Ges | Verfahren zur Darstellung von Dipyrrolen |
| US3632805A (en) | 1967-12-08 | 1972-01-04 | Sumitomo Chemical Co | Process for producing 1-aminoalkyl-benzodiazepine derivatives |
| AU575854B2 (en) | 1983-10-04 | 1988-08-11 | Shionogi & Co., Ltd. | 7beta-(carboxyalkenamido) cephalosporins |
| NZ220764A (en) | 1986-07-02 | 1989-09-27 | Shionogi & Co | Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions |
| US5017380A (en) | 1986-07-02 | 1991-05-21 | Shionogi & Co., Ltd. | Gelatin hard capsule containing crystalline hydrate of oral cephalosporin |
| CA2038925A1 (en) | 1990-03-26 | 1991-09-27 | Takashi Sohda | Indole derivatives, their production and use |
| JPH04149429A (ja) | 1990-10-12 | 1992-05-22 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー反転写真感光材料およびそれを用いた画像形成方法 |
| IT1278077B1 (it) | 1995-05-25 | 1997-11-17 | Angeletti P Ist Richerche Bio | Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal |
| US5922757A (en) | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
| EP0932617B1 (en) | 1996-10-18 | 2002-01-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| PT1012180E (pt) | 1997-08-11 | 2005-04-29 | Boehringer Ingelheim Ca Ltd | Analogos de peptidos inibidores da hepatite c |
| FR2768146B1 (fr) | 1997-09-05 | 2000-05-05 | Oreal | Nouveaux composes de la famille des indole-carboxyliques et leur utilisation |
| CN1441806A (zh) | 2000-04-05 | 2003-09-10 | 先灵公司 | 包含n－环p2部分的丙型肝炎病毒的大环ns3－丝氨酸蛋白酶抑制剂 |
| NZ521456A (en) | 2000-04-19 | 2004-07-30 | Schering Corp | Macrocyclic NS3-Serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties |
| CZ2003195A3 (cs) | 2000-07-21 | 2003-04-16 | Schering Corporation | Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostředek |
| IL153670A0 (en) | 2000-07-21 | 2003-07-06 | Schering Corp | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
| AR034127A1 (es) | 2000-07-21 | 2004-02-04 | Schering Corp | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento |
| JP2004529855A (ja) | 2000-10-10 | 2004-09-30 | スミスクライン ビーチャム コーポレーション | 置換インドール類、そのような置換インドール類を含む医薬組成物及びＰＰＡＲ−γ結合剤としてのそれらの使用 |
| AU3659102A (en) | 2000-12-12 | 2002-06-24 | Schering Corp | Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus |
| US6974831B2 (en) | 2000-12-18 | 2005-12-13 | Eli Lilly And Company | sPLA2 inhibitors |
| ES2299560T3 (es) | 2001-02-22 | 2008-06-01 | University Of Bradford | Derivados de pirrolindol y de pirroloquinolina como profarmacos para el tratamiento de tumores. |
| EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| US20050215614A1 (en) | 2002-10-15 | 2005-09-29 | Rigel Pharmaceuticals, Inc. | Substituted indoles and their use as hcv inhibitors |
| US20050075331A1 (en) | 2003-10-06 | 2005-04-07 | Pratt John K. | Anti-infective agents |
| ATE546456T1 (de) | 2003-05-30 | 2012-03-15 | Gemin X Pharmaceuticals Canada Inc | Triheterocyclische verbindungen, zusammensetzungen, und verfahren zur behandlung von krebs |
| GB0323845D0 (en) * | 2003-10-10 | 2003-11-12 | Angeletti P Ist Richerche Bio | Chemical compounds,compositions and uses |
| AR046833A1 (es) | 2003-11-10 | 2005-12-28 | Schering Corp | Anticuerpos anti-interleuquina-10 |
| EP1714427A1 (de) | 2004-02-09 | 2006-10-25 | Hörmann KG Antriebstechnik | Torantriebssystem mit seriellem bus für kommunikation der komponenten |
| DK1730110T3 (da) | 2004-02-27 | 2010-09-27 | Schering Corp | Svovlforbindelser som inhibitorer af hepatitis C-virus NS3-serinprotease |
| JP2007526320A (ja) * | 2004-03-01 | 2007-09-13 | バイロファーマ・インコーポレイテッド | ピラノインドール誘導体およびｃ型肝炎ウイルス感染症または疾患の治療のためのその使用 |
| PE20060309A1 (es) | 2004-05-06 | 2006-04-13 | Schering Corp | (1r,2s,5s)-n-[(1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil]-3-[(2s)-2[[[(1,1-dimetiletil)amino]carbonil]amino]-3,3-dimetil-1-oxobutil]-6,6-dimetil-3-azabiciclo[3.1.o]hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de l |
| EP1604988A1 (en) | 2004-05-18 | 2005-12-14 | Sanofi-Aventis Deutschland GmbH | Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals |
| WO2007084413A2 (en) | 2004-07-14 | 2007-07-26 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
| US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| WO2006034337A2 (en) | 2004-09-23 | 2006-03-30 | Wyeth | Carbazole and cyclopentaindole derivatives to treat infection with hepatitis c virus |
| DE102004047272A1 (de) | 2004-09-24 | 2006-04-06 | Schering Ag | Inhibitoren der löslichen Adenylatzyklase |
| US7662809B2 (en) | 2004-10-26 | 2010-02-16 | Istituto Di Richerche Di Biologia Molecolare P Angeletti Spa | Tetracyclic indole derivatives as antiviral agents |
| US20110104109A1 (en) | 2005-07-13 | 2011-05-05 | Frank Bennett | Tetracyclic indole derivatives and their use for treating or preventing viral infections |
| GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| CA2623026A1 (en) | 2005-09-23 | 2007-04-05 | Schering Corporation | Fused tetracyclic mglur1 antagonists as therapeutic agents |
| JP2009523732A (ja) | 2006-01-13 | 2009-06-25 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｃ型肝炎の治療方法 |
| WO2007092616A2 (en) | 2006-02-09 | 2007-08-16 | Schering Corporation | Combinations comprising hcv protease inhibitor(s) and hcv polymerase inhibitor(s), and methods of treatment related thereto |
| WO2008082488A1 (en) | 2006-12-22 | 2008-07-10 | Schering Corporation | 4, 5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections |
| CN101611025A (zh) | 2006-12-22 | 2009-12-23 | 先灵公司 | 5,6-环化的吲哚衍生物及其使用方法 |
| WO2008082484A1 (en) * | 2006-12-22 | 2008-07-10 | Schering Corporation | 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections |
| BRPI0816116A2 (pt) | 2007-08-29 | 2015-03-03 | Schering Corp | Derivados de indol 2,3-substituídos para o tratamento de infecções virais. |
| AU2008295484B2 (en) | 2007-08-29 | 2013-09-26 | Merck Sharp & Dohme Llc | Substituted indole derivatives and methods of use thereof |
| TW200918536A (en) * | 2007-08-29 | 2009-05-01 | Schering Corp | Tetracyclic indole derivatives and methods of use thereof |
| TW200911807A (en) | 2007-08-29 | 2009-03-16 | Schering Corp | 2,3-substituted azaindole derivatives and methods of use thereof |
| CN102317285A (zh) | 2007-11-16 | 2012-01-11 | 先灵公司 | 3-氨基磺酰基取代的吲哚衍生物及其使用方法 |
| MX2010005356A (es) | 2007-11-16 | 2010-05-27 | Schering Corp | Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos. |
-
2009
- 2009-06-10 AR ARP090102091A patent/AR072088A1/es not_active Application Discontinuation
- 2009-06-10 CN CN200980131569.9A patent/CN102159579B/zh active Active
- 2009-06-10 WO PCT/US2009/046822 patent/WO2009152200A1/en not_active Ceased
- 2009-06-10 EP EP09763490.1A patent/EP2303893B1/en not_active Not-in-force
- 2009-06-10 US US12/997,654 patent/US8901139B2/en active Active
- 2009-06-10 JP JP2011513649A patent/JP5580814B2/ja active Active
- 2009-06-10 MX MX2010013630A patent/MX2010013630A/es active IP Right Grant
- 2009-06-10 CA CA2727620A patent/CA2727620A1/en not_active Abandoned
- 2009-06-11 TW TW098119583A patent/TW201011030A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2303893A1 (en) | 2011-04-06 |
| MX2010013630A (es) | 2010-12-21 |
| US20110189127A1 (en) | 2011-08-04 |
| WO2009152200A1 (en) | 2009-12-17 |
| US8901139B2 (en) | 2014-12-02 |
| TW201011030A (en) | 2010-03-16 |
| EP2303893B1 (en) | 2016-12-07 |
| CA2727620A1 (en) | 2009-12-17 |
| JP2011524359A (ja) | 2011-09-01 |
| CN102159579B (zh) | 2015-03-25 |
| CN102159579A (zh) | 2011-08-17 |
| JP5580814B2 (ja) | 2014-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072088A1 (es) | Derivados de indol triciclicos y sus metodos de uso | |
| CL2012000999A1 (es) | Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina. | |
| PE20080257A1 (es) | Derivados de triazol ii | |
| AR065499A1 (es) | Inhibidores de serino proteasas.composiciones farmaceuticas | |
| AR068107A1 (es) | Derivados indolicos 2,3 sustituidos y una composicion farmaceutica | |
| AR084976A1 (es) | Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| AR066155A1 (es) | Compuestos de pirazol, simil tiroideo, composicion farmaceutica, proceso y uso en terapia | |
| AR117189A1 (es) | Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb) | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| ECSP109932A (es) | Compuestos de biciclolactama sustituida | |
| AR066448A1 (es) | Inhibidores macrociclicos de la replicacion del virus de hepatitis c, composicion farmaceutica, metodos de obtencion del compuesto y compuestos intermediarios | |
| AR044005A1 (es) | Compuestos biciclicos, procedimiento para su preparacion, su uso para preparar un medicamento y composiciones farmaceuticas que los comprenden | |
| AR071823A1 (es) | Derivados heterociclicos de imidazol y pirazol, inhibidores del factor ixa de coagulacion, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diversos trastornos tromboembolicos. | |
| RU2012117829A (ru) | Фосфорамидатные производные нуклеозидов | |
| AR061629A1 (es) | Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas | |
| AR058546A1 (es) | Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1 | |
| UY31950A (es) | Inhibidores de ciclopropil-polimerasa | |
| AR052256A1 (es) | Derivados de tetrahidropirano y su uso como agentes antidiabeticos | |
| AR073263A1 (es) | Derivados de piridina y su uso en diagnostico de imagenes mediante pet | |
| EA201600241A1 (ru) | Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты | |
| AR061305A1 (es) | Agonistas de receptores muscarinicos | |
| AR067060A1 (es) | Derivados de guanina policiclicos y sus metodos de uso | |
| CO6190627A2 (es) | Derivados de acetileno y su uso para la union a placas amiloides y su diagnostico por imagenes | |
| AR071833A1 (es) | Inhibidores de quinasas (limk2), composiciones que los comprenden y metodos para tratar o prevenir enfermedades | |
| AR081377A1 (es) | Compuestos de pirazolopiridina bifuncionales |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |